A Greenburg Traurig team represented Intec Pharma Ltd. in a public offering that raised $57.5 million that the company intends to use to fund further clinical trials of a product that could improve the treatment of symptoms of advanced Parkinson’s disease.
The platform technology on which the product is based is also part of a proposed medical marijuana drug that is in clinical trials in Israel.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
